OFEV Has Been Proven to
Slow IPF Progression

OFEV® (nintedanib) reduces disease progression
in 2 ways...

OFEV slows the decline in lung function

  • In 2 out of 3 medical studies, OFEV capsules were proven to slow the decline in lung function by about 50% compared to IPF patients who took a placebo, a pill with no medicine
  • In the third study, OFEV slowed the decline in lung function by 68%. This was determined by testing patients' forced vital capacity, or FVC, after 1 year of therapy. FVC is the amount of air you can forcibly blow out, or exhale, after taking the deepest breath possible

OFEV reduces acute exacerbations

A small number of patients with IPF may experience a serious and sudden worsening of symptoms, known as an acute exacerbation. These acute exacerbations cause a sudden and permanent worsening of IPF that leaves the patient with less lung function than they had before the attack.

  • In 2 out of 3 medical studies, OFEV reduced the chances of having a first acute exacerbation during a 1-year period
  • In 1 study, OFEV patients were 80% less likely to have an acute exacerbation during a 1-year period vs placebo patients (7.3% vs 1.5%, respectively, with an absolute difference of 5.8%)
80% less risk of an acute exacerbation
OFEV® (nintedanib) Package


You are now leaving a Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) site. BIPI is not responsible and disclaims any liability for the content or for any viruses or similar harmful programs that may be present on third-party pages or sites. Visit any other page or site at your own risk.


Stay on this site